L-ASP — Competitive Intelligence Brief

L-ASP (L-ASP) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Enzyme (asparagine depleting agent). Area: Oncology.

phase 3 Enzyme (asparagine depleting agent) Asparagine Oncology Small molecule

Target snapshot

L-ASP (L-ASP) — First Affiliated Hospital of Zhejiang University. L-ASP (L-asparaginase) depletes the amino acid asparagine in leukemic cells, which cannot synthesize their own asparagine and thus undergo apoptosis.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
L-ASP TARGET	L-ASP	First Affiliated Hospital of Zhejiang University	phase 3	Enzyme (asparagine depleting agent)	Asparagine
Asparlas	calaspargase	Pfizer	marketed	Asparagine-specific Enzyme [EPC]	L-asparagine	2018-01-01
ASPARAGINASE ERWINIA CHRYSANTHEMI	ASPARAGINASE ERWINIA CHRYSANTHEMI		marketed	Asparagine-specific Enzyme [EPC]	L-asparagine	2011-01-01
Elspar	ASPARAGINASE	Merck & Co.	marketed	Asparagine-specific Enzyme [EPC]	L-asparagine	1994-01-01
L-asparaginase	L-asparaginase	ERYtech Pharma	marketed	Enzyme (asparagine depleting agent)	Asparagine (substrate depletion mechanism)
Erwinia asparaginase	Erwinia asparaginase	Andrew E. Place, MD	marketed	Enzyme	Asparagine
Fe-ASP	Fe-ASP	Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.	marketed	Asparaginase conjugate	Asparagine synthetase (indirect target via asparagine depletion)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Enzyme (asparagine depleting agent) class)

1. ERYtech Pharma · 1 drug in this class
2. First Affiliated Hospital of Zhejiang University · 1 drug in this class
3. Rigshospitalet, Denmark · 1 drug in this class